Immunoinformatics-Driven Rational Design of Altered Peptide Ligands and In Vitro Validation of a Multi-Epitope CTL Formulation Targeting HPV16 E6/E7
Vaccines · 20.08.2026 · 14 (8) · 715
DOI: 10.3390/vaccines14080715 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 20.08.2026. Verfasst von Dian Dong und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Therapeutic vaccination against human papillomavirus type 16 (HPV16) is frequently limited by the weak HLA-A*02:01 presentation of native E6/E7 oncoprotein epitopes. This study aims to utilize an integrated computational-experimental pipeline to design and evaluate anchor-optimized altered peptide ligands (APLs) for improving peptide presentation and HPV16-specific T-cell responses.
Methods
Anchor-residue substitutions were introduced into three wild-type E6/E7 epitopes. Candidates were prioritized in silico based on predicted presentation, affinity, immunogenicity, and toxicity, and subsequently evaluated via in vitro functional assays using HLA-A*02:01-positive donor cells and molecular dynamics (MD) simulations.
Results
Anchor optimization successfully converted weak binders into strong binders; for instance, E6apl improved predicted affinity from 329.33 to 6.21 nM. Crucially, candidate E7apl1 exhibited normal CD8+ T-cell expansion but reduced IFN-γ secretion, revealing a distinct binding–immunogenicity dissociation. MD simulations suggested that altered peptide conformational dynamics may contribute to differences in functional activity. Subsequently, an optimized six-peptide formulation (three APLs and three wild-type epitopes) was assembled. The resulting multi-epitope HPV-specific cytotoxic T lymphocytes (meHPV-CTLs) mediated target-specific cytotoxicity against cervical cancer cells, achieving 74.1% ± 5.1% specific lysis at an effector-to-target ratio of 30:1, which was largely abrogated by HLA class I blockade.
Conclusions
These proof-of-concept findings demonstrate that stable peptide–MHC binding is a necessary but insufficient condition for optimal T-cell activation. The experimentally characterized multi-epitope formulation provides a proof-of-concept strategy for further preclinical evaluation of HPV16-targeted peptide-based immunotherapies. Moreover, because these anchor-optimized APLs are defined at the sequence level, these sequence-defined APLs may potentially be explored in alternative vaccine delivery platforms, including mRNA-based approaches, in future studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
- BGI Research, Shenzhen 518083, China.
ORCID-Profile: Dian Dong
Zitieren
APA
Dong, D., Zhang, X., & Li, B. (2026). Immunoinformatics-Driven Rational Design of Altered Peptide Ligands and In Vitro Validation of a Multi-Epitope CTL Formulation Targeting HPV16 E6/E7. Vaccines, 14(8), 715. https://doi.org/10.3390/vaccines14080715
Vancouver
Dong D, Zhang X, Li B. Immunoinformatics-Driven Rational Design of Altered Peptide Ligands and In Vitro Validation of a Multi-Epitope CTL Formulation Targeting HPV16 E6/E7. Vaccines. 2026;14(8):715. doi:10.3390/vaccines14080715
BibTeX
@article{Dong2026,
author = {Dong, Dian and Zhang, Xiuqing and Li, Bo},
title = {Immunoinformatics-Driven Rational Design of Altered Peptide Ligands and In Vitro Validation of a Multi-Epitope CTL Formulation Targeting HPV16 E6/E7},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {8},
pages = {715},
doi = {10.3390/vaccines14080715}
}
EUVIMED